DK1644336T3 - Nitrogenholdige heteroarylforbindelser og deres anvendelse til forøgelse af endogent erythropoietin - Google Patents

Nitrogenholdige heteroarylforbindelser og deres anvendelse til forøgelse af endogent erythropoietin

Info

Publication number
DK1644336T3
DK1644336T3 DK04754384.8T DK04754384T DK1644336T3 DK 1644336 T3 DK1644336 T3 DK 1644336T3 DK 04754384 T DK04754384 T DK 04754384T DK 1644336 T3 DK1644336 T3 DK 1644336T3
Authority
DK
Denmark
Prior art keywords
nitrogen
increasing endogenous
containing heteroaryl
heteroaryl compounds
endogenous erythropoietin
Prior art date
Application number
DK04754384.8T
Other languages
English (en)
Inventor
Michael P Arend
Xiaohui Du
Lee A Flippin
Volkmar Guenzler-Pukall
Wen-Bin Ho
Eric D Turtle
Original Assignee
Fibrogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fibrogen Inc filed Critical Fibrogen Inc
Application granted granted Critical
Publication of DK1644336T3 publication Critical patent/DK1644336T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/08—Aza-anthracenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK04754384.8T 2003-06-06 2004-06-04 Nitrogenholdige heteroarylforbindelser og deres anvendelse til forøgelse af endogent erythropoietin DK1644336T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US47663303P 2003-06-06 2003-06-06
US47651903P 2003-06-06 2003-06-06
US47642003P 2003-06-06 2003-06-06
US47681103P 2003-06-06 2003-06-06
PCT/US2004/017773 WO2004108681A1 (en) 2003-06-06 2004-06-04 Nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin

Publications (1)

Publication Number Publication Date
DK1644336T3 true DK1644336T3 (da) 2011-05-09

Family

ID=33514880

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04754384.8T DK1644336T3 (da) 2003-06-06 2004-06-04 Nitrogenholdige heteroarylforbindelser og deres anvendelse til forøgelse af endogent erythropoietin

Country Status (22)

Country Link
US (12) US7323475B2 (da)
EP (2) EP2357175A1 (da)
JP (3) JP2006527200A (da)
KR (1) KR100932169B1 (da)
CN (5) CN102718708A (da)
AT (1) ATE496033T1 (da)
AU (1) AU2004245552B2 (da)
BR (1) BRPI0411055B1 (da)
CA (1) CA2528232C (da)
CY (1) CY1111616T1 (da)
DE (1) DE602004031114D1 (da)
DK (1) DK1644336T3 (da)
ES (1) ES2362032T3 (da)
HK (1) HK1090367A1 (da)
HR (1) HRP20110272T1 (da)
IL (1) IL171758A (da)
NO (1) NO334949B1 (da)
NZ (1) NZ543448A (da)
PL (1) PL1644336T3 (da)
PT (1) PT1644336E (da)
SI (1) SI1644336T1 (da)
WO (1) WO2004108681A1 (da)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8614204B2 (en) * 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
PL1644336T3 (pl) 2003-06-06 2011-07-29 Fibrogen Inc Związki heteroarylowe zawierające azot i ich zastosowanie w zwiększaniu poziomu endogennej erytropoetyny
JP2007501844A (ja) * 2003-08-08 2007-02-01 トランス　テック　ファーマ，インコーポレイテッド アリール及びヘテロアリール化合物、組成物並びに使用方法
AU2004275720B2 (en) 2003-09-23 2008-04-24 Merck Sharp & Dohme Corp. Isoquinoline potassium channel inhibitors
CN1901795B (zh) * 2003-10-22 2014-03-26 弗雷德哈钦森癌症研究中心 用于在细胞，组织，器官，和有机体中诱导停滞的方法，组合物和装置
US20050170019A1 (en) * 2003-10-22 2005-08-04 Fred Hutchinson Cancer Research Center Methods, compositions and devices for inducing stasis in cells
US20050136125A1 (en) * 2003-10-22 2005-06-23 Roth Mark B. Methods, compositions and devices for inducing stasis in cells, tissues, organs, and organisms
EP1676834A1 (en) * 2004-12-30 2006-07-05 Sanofi-Aventis Deutschland GmbH Fused bicyclic carboxamide derivates for use as CXCR2 inhibitors in the treatment of inflammation
JP4792048B2 (ja) 2005-03-02 2011-10-12 ファイブロゲン インコーポレイティッド チエノピリジン化合物およびその使用方法
AR055319A1 (es) * 2005-03-17 2007-08-15 Wyeth Corp Derivados de isoquinoleina, composiciones farmaceuticas y usos
AU2006236150A1 (en) 2005-04-20 2006-10-26 Fred Hutchinson Cancer Research Center Methods, compositions and articles of manufacture for enhancing survivability of cells, tissues, organs, and organisms
JP5390184B2 (ja) * 2005-06-06 2014-01-15 ファイブローゲン、インコーポレーテッド 貧血の改良された治療方法
CN101242817B (zh) 2005-06-15 2016-08-31 菲布罗根公司 HIF1α调节剂在治疗癌症中的用途
US7728130B2 (en) * 2005-12-09 2010-06-01 Amgen Inc. Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity
WO2007082899A1 (en) * 2006-01-17 2007-07-26 Vib Vzw Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration
KR100821649B1 (ko) * 2006-01-24 2008-04-11 서울시립대학교 산학협력단 클리오퀴놀을 유효성분으로 포함하는 ＨＩＦ-1α 활성제
MX2008009581A (es) * 2006-01-27 2009-01-07 Fibrogen Inc Compuestos de cianoisoquinolina que estabilizan el factor inducible hipoxia (fih).
CN101420980A (zh) 2006-02-16 2009-04-29 菲布罗根公司 治疗中风的化合物和方法
WO2007101204A1 (en) * 2006-02-27 2007-09-07 Alcon Research, Ltd. Method of treating glaucoma
US7745461B1 (en) 2006-02-27 2010-06-29 Alcon Research, Ltd. Method of treating dry eye disorders
AR059733A1 (es) * 2006-03-07 2008-04-23 Smithkline Beecham Corp Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacion
US7588924B2 (en) 2006-03-07 2009-09-15 Procter & Gamble Company Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
MX2008012734A (es) * 2006-04-04 2009-01-29 Fibrogen Inc Compuestos pirrolo- y tiazolo-piridina como moduladores del factor inducible de hipoxia (hif).
US7713986B2 (en) 2006-06-15 2010-05-11 Fibrogen, Inc. Compounds and methods for treatment of chemotherapy-induced anemia
US20070293575A1 (en) * 2006-06-15 2007-12-20 Fibrogen, Inc. Compounds and methods for treatment of cancer-related anemia
PE20080209A1 (es) 2006-06-23 2008-05-15 Smithkline Beecham Corp Derivados de glicina como inhibidores de prolil hidroxilasa
EP3026044B8 (en) * 2006-06-26 2018-12-19 Akebia Therapeutics, Inc. Prolyl hydroxylase inhibitors and methods of use
JP5232144B2 (ja) 2006-06-28 2013-07-10 サノフイ Ｃｘｃｒ２阻害剤
KR20090023645A (ko) 2006-06-28 2009-03-05 사노피-아벤티스 신규한 ｃｘｃｒ2 억제제
EP2041072B1 (en) 2006-06-28 2013-09-11 Sanofi Cxcr2 antagonists
JP5352455B2 (ja) 2006-06-30 2013-11-27 サノフイ Ｃｘｃｒ２阻害剤
US20090011051A1 (en) * 2006-09-28 2009-01-08 Roth Mark B Methods, Compositions and Articles of Manufacture for HIF Modulating Compounds
EP2097416B1 (en) * 2006-12-18 2012-09-12 Amgen, Inc Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
WO2008076427A2 (en) * 2006-12-18 2008-06-26 Amgen Inc. Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
US7569726B2 (en) 2007-04-18 2009-08-04 Amgen Inc. Indanone derivatives that inhibit prolyl hydroxylase
JP2010524942A (ja) 2007-04-18 2010-07-22 アムジエン・インコーポレーテツド プロリルヒドロキシラーゼを阻害するキノロン及びアザキノロン
AU2008248165B2 (en) 2007-05-04 2011-12-08 Amgen Inc. Diazaquinolones that inhibit prolyl hydroxylase activity
EP2150251B9 (en) * 2007-05-04 2013-02-27 Amgen, Inc Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity
US8962530B2 (en) * 2007-06-27 2015-02-24 Regents Of The University Of Colorado Inflammatory bowel disease therapies
WO2009058403A1 (en) * 2007-11-02 2009-05-07 Fibrogen, Inc. Methods for reducing blood pressure
EP2227475B1 (en) 2007-12-03 2014-02-19 Fibrogen, Inc. Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions
WO2009075824A1 (en) * 2007-12-06 2009-06-18 Fibrogen, Inc. Methods for increasing endothelial progentior cells
US20110039879A1 (en) * 2007-12-07 2011-02-17 FibroGen ,Inc. Methods for increasing white blood cells
WO2009089547A1 (en) * 2008-01-11 2009-07-16 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity
US8324405B2 (en) 2008-02-05 2012-12-04 Fibrogen, Inc. Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors
US20110112103A1 (en) * 2008-04-22 2011-05-12 Daiichi Sankyo Company, Limited 5-hydroxypyrimidine-4-carboxamide compound
CN102076680B (zh) 2008-04-28 2016-03-02 詹森药业有限公司 作为脯氨酰羟化酶抑制剂的苯并咪唑
EP2334682B1 (en) * 2008-08-20 2017-10-04 Fibrogen, Inc. Pyrrolo [ 1, 2 -b] pyridazine derivatives and their use as hif modulators
WO2010022307A2 (en) * 2008-08-21 2010-02-25 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
US8927591B2 (en) 2008-11-14 2015-01-06 Fibrogen, Inc. Thiochromene derivatives as HIF hydroxylase inhibitors
AU2010266558A1 (en) * 2009-06-30 2012-01-12 Merck Sharp & Dohme Corp. Substituted 4-hydroxypyrimidine-5-carboxamides
UA107360C2 (en) 2009-08-05 2014-12-25 Biogen Idec Inc Bicyclic aryl sphingosine 1-phosphate analogs
AU2010308942C1 (en) * 2009-10-21 2017-04-20 Daiichi Sankyo Company,Limited 5-hydroxypyrimidine-4-carboxamide derivative
AR079022A1 (es) 2009-11-02 2011-12-21 Sanofi Aventis Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion
WO2011056725A1 (en) * 2009-11-05 2011-05-12 Crystalgenomics, Inc. Pyridine derivatives and methods of use thereof
CN102595896B (zh) 2009-11-06 2016-02-17 爱尔皮奥治疗有限公司 提高低氧诱导因子-1α的稳定性的方法
WO2012097331A1 (en) * 2011-01-13 2012-07-19 Fibrogen, Inc. Methods for increasing reticulocyte hemoglobin content
WO2012097329A1 (en) 2011-01-13 2012-07-19 Fibrogen, Inc. Methods for increasing mean corpuscular volume
US8921389B2 (en) 2011-02-02 2014-12-30 Fibrogen, Inc. Naphthyridine derivatives as inhibitors of hypoxia inducible factor (HIF) hydroxylase
UA113507C2 (xx) 2011-02-07 2017-02-10 Модулятори s1p
NO2686520T3 (da) 2011-06-06 2018-03-17
WO2012170439A1 (en) 2011-06-06 2012-12-13 The Ohio State University Methods for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
WO2013003315A2 (en) * 2011-06-26 2013-01-03 President And Fellows Of Harvard College Methods for preparing isoquinolines
JP2014520776A (ja) * 2011-07-04 2014-08-25 バイエル・インテレクチユアル・プロパテイー・ゲー・エム・ベー・ハー 植物における非生物的ストレスに対する活性薬剤としての置換されているイソキノリノン類、イソキノリンジオン類、イソキノリントリオン類およびジヒドロイソキノリノン類または各場合でのそれらの塩の使用
JP6099644B2 (ja) * 2011-07-22 2017-03-22 ベイジン ベータ ファーマシューティカルズ カンパニー， リミテッド プロリルヒドロキシラーゼ阻害剤としての化合物の多形体、およびその使用
HUE052128T2 (hu) 2011-10-25 2021-04-28 Janssen Pharmaceutica Nv Eljárás az 1-(5,6-diklór-1H-benzo[d]imidazol-2-il)-1H-pirazol-4-karbonsav meglumin sója kristályainak elõállítására
US9409892B2 (en) 2012-03-09 2016-08-09 Fibrogen, Inc. 4-hydroxy-isoquinoline compounds as HIF hydroxylase inhibitors
CN104427980A (zh) * 2012-03-09 2015-03-18 菲布罗根有限公司 高胆固醇的治疗
SI3470397T1 (sl) 2012-07-16 2022-07-29 Fibrogen, Inc. Kristalinične oblike zaviralca prolil hidroksilaze
ES2631655T3 (es) 2012-07-16 2017-09-01 Fibrogen, Inc. Procedimiento para fabricar compuestos de isoquinolina
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
EP2877166B1 (en) * 2012-07-27 2018-02-28 Biogen MA Inc. 1-[7-(cis-4-methyl-cyclohexyloxy)-8-trifluoromethyl-naphthalen-2-ylmethyl]-piperidine-4-carboxylic acid derivatives as autotaxin (ATX) modulators for treating inflammations and autoimmune disorders
CA2880165C (en) 2012-07-30 2020-02-11 Taisho Pharmaceutical Co., Ltd. Partially saturated nitrogen-containing heterocyclic compound
TWI598339B (zh) 2012-12-24 2017-09-11 卡地拉保健有限公司 新穎喹啉酮衍生物
TWI582078B (zh) * 2013-01-23 2017-05-11 北京貝美拓新藥研發有限公司 抑制脯氨酸羥化酶活性的化合物的晶型及其應用
KR102233081B1 (ko) 2013-01-24 2021-03-29 피브로겐, 인크. 〔[1-시아노-5-(4-클로로페녹시)-4-하이드록시-아이소퀴놀린-3-카보닐]-아미노〕-아세트산의 결정 형태
TWI660945B (zh) * 2013-02-22 2019-06-01 費比羅根公司 脯胺醯羥化酶抑制劑的晶體形態
CN105377251A (zh) * 2013-03-01 2016-03-02 马特医疗研究中心有限公司 动员剂及其用途
DK3003284T3 (da) * 2013-06-06 2020-03-30 Fibrogen Inc Farmaceutiske formuleringer af en hif-hydroxylase-inhibitor
CN114404414A (zh) 2013-06-13 2022-04-29 阿克比治疗有限公司 用于治疗贫血症的组合物和方法
US10644503B2 (en) 2013-10-29 2020-05-05 Massachusetts Institute Of Technology Coupled split path power conversion architecture
AR099354A1 (es) 2013-11-15 2016-07-20 Akebia Therapeutics Inc Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones, y sus usos
WO2015095757A1 (en) * 2013-12-19 2015-06-25 The Cleveland Clinic Foundation Treatment of retinopathy of prematurity (rop)
CN103694172A (zh) * 2013-12-26 2014-04-02 辽宁亿灵科创生物医药科技有限公司 含氮杂芳基化合物的衍生物
EP2915878A1 (en) 2014-03-07 2015-09-09 Institut Pasteur Method and device for conserving viable and functional human polymorphonuclear neutrophils
JP6506390B2 (ja) * 2014-09-02 2019-04-24 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． キノリノン系化合物及びその薬物への使用
WO2016118858A1 (en) 2015-01-23 2016-07-28 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
CN106146395B (zh) * 2015-03-27 2019-01-01 沈阳三生制药有限责任公司 3-羟基吡啶化合物、其制备方法及其制药用途
CN106146491B (zh) * 2015-03-27 2017-12-12 沈阳三生制药有限责任公司 被芳基或杂芳基取代的5‑羟基‑1,7‑萘啶化合物、其制备方法及其制药用途
CN106146490B (zh) * 2015-03-27 2018-10-23 沈阳三生制药有限责任公司 被芳氧基或杂芳氧基取代的5-羟基-1,7-萘啶化合物、其制备方法及其制药用途
BR112017021097B1 (pt) 2015-04-01 2024-01-02 Akebia Therapeutics, Inc Formulação de dosagem oral e seu uso
CN109180580B (zh) * 2016-02-28 2021-01-12 深圳市塔吉瑞生物医药有限公司 一种取代的杂芳基化合物及包含该化合物的组合物及其用途
CZ2016627A3 (cs) 2016-10-07 2018-04-18 Zentiva, K.S. Způsob přípravy (7-fenoxy-4-hydroxy-1-methylisochinolin-3-karbonyl)glycinu (roxadustatu) a jeho intermediátů založený na souběžném otevírání oxazolového kruhu, štěpení etheru a tvorbě iminu
CN108017583B (zh) * 2016-11-01 2021-04-06 徐州万邦金桥制药有限公司 一种可博美的制备方法
GB2561540A (en) 2017-03-13 2018-10-24 Nodthera Ltd Chemical compounds
CN108484598B (zh) 2017-05-09 2021-03-02 杭州安道药业有限公司 吲哚嗪衍生物及其在医药上的应用
CN107382986B (zh) * 2017-08-02 2022-09-20 江苏艾立康医药科技有限公司 4-羟基-1-甲基异喹啉衍生物及其在增加内源性促红细胞生成素中的用途
CN111511371A (zh) 2017-08-11 2020-08-07 雷迪博士实验室有限公司 罗沙司他的多晶型物和共晶
WO2019042485A1 (en) 2017-08-30 2019-03-07 Zentiva, K.S. FORMS IN THE STRONG STATE OF ROXADUSTAT
CN111065625A (zh) 2017-09-04 2020-04-24 桑多斯股份公司 口服可利用的hif脯氨酰羟化酶抑制剂的共晶
CN111566090A (zh) * 2017-12-01 2020-08-21 雷迪博士实验室有限公司 罗沙司他及其中间体的制备方法
CN109956870A (zh) 2017-12-14 2019-07-02 南京卡文迪许生物工程技术有限公司 一种罗沙司他的合成方法及其中间体化合物
WO2019148471A1 (zh) * 2018-02-02 2019-08-08 中国人民解放军军事科学院军事医学研究院 Fg-4592或其盐的新用途以及药品和保健品
CN108424388B (zh) * 2018-04-19 2020-08-21 杭州科巢生物科技有限公司 一种慢性贫血药物的制备方法
TWI822776B (zh) 2018-05-09 2023-11-21 美商阿克比治療有限公司 用於製備2-[[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基]乙酸之方法
CN110507655B (zh) * 2018-05-22 2022-10-28 厦门大学 化合物fg-4592在制备治疗甲状腺激素受体介导疾病的药物制剂中的应用
CN110878096A (zh) * 2018-09-05 2020-03-13 石药集团中奇制药技术（石家庄）有限公司 一种1,7-萘啶类衍生物及其制备方法和用途
CN111349077B (zh) * 2019-02-02 2022-06-28 杭州华东医药集团新药研究院有限公司 一种哒嗪衍生物及其制备方法和医药用途
WO2020178847A1 (en) 2019-03-01 2020-09-10 Mylan Laboratories Limited Cocrystal of roxadustat and d-proline
CN109776415B (zh) * 2019-03-07 2020-11-17 福建南方制药股份有限公司 一种Roxadustat中间体的制备方法
TW202120490A (zh) 2019-07-30 2021-06-01 德商拜耳動物保健有限公司 新穎異喹啉衍生物
WO2021026307A1 (en) 2019-08-07 2021-02-11 Teva Pharmaceuticals International Gmbh Processes for the preparation of roxadustat and intermediates thereof
CN112679431B (zh) * 2019-10-18 2023-05-05 上海迪赛诺化学制药有限公司 一种制备异喹啉酮类化合物的方法
CN112679430B (zh) * 2019-10-18 2023-05-05 上海迪赛诺化学制药有限公司 一种制备异喹啉酮类化合物的方法
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
MX2022011534A (es) * 2020-03-19 2022-10-13 Arcus Biosciences Inc Compuestos de tetralina y tetrahidroquinolina como inhibidores de hif-2alfa.
CN111393365B (zh) * 2020-03-24 2022-04-19 山东百诺医药股份有限公司 一种罗沙司他的制备方法
WO2021216530A1 (en) 2020-04-20 2021-10-28 Akebia Therapeutics, Inc. Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer
WO2021214785A1 (en) 2020-04-21 2021-10-28 Mylan Laboratories Limited Improved process for the preparation of roxadustat
CN114644589A (zh) * 2020-12-17 2022-06-21 鲁南制药集团股份有限公司 一种化合物n-[（4-羟基--1-甲基-3-异喹啉基）羰基]-甘氨酸的制备方法
WO2022150623A1 (en) 2021-01-08 2022-07-14 Akebia Therapeutics, Inc. Compounds and composition for the treatment of anemia
CN115144480B (zh) * 2021-03-31 2023-11-28 成都倍特药业股份有限公司 一种从罗沙司他中间体中检测吗啉和/或四甲基甲烷二胺的方法
WO2022251563A1 (en) 2021-05-27 2022-12-01 Keryx Biopharmaceuticals, Inc. Pediatric formulations of ferric citrate
WO2023095162A1 (en) 2021-11-26 2023-06-01 Mylan Laboratories Limited Cocrystal of roxadustat and nicotinamide
CN116554057B (zh) * 2023-05-05 2023-12-15 杭州安道药业有限公司 降低促红细胞生长素（epo）生成的化合物及其用途

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036964A (en) 1973-10-11 1977-07-19 Beecham Group Limited Isocarbostyril-3-carboxylic acid derivatives for the prophylaxis of asthma, hayfever and rhinitis
US3989704A (en) 1973-10-30 1976-11-02 Sandoz, Inc. 3-Substituted-4-aryl isoquinolines
DE2818423A1 (de) 1978-04-27 1979-11-08 Hoechst Ag Neue isochinolinderivate und verfahren zu ihrer herstellung
DE3233424A1 (de) 1982-09-09 1984-03-15 Hoechst Ag, 6230 Frankfurt Isochinolinderivate, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
US4559403A (en) 1983-05-19 1985-12-17 Hoffmann-La Roche Inc. Substituted isoquinolines
US4584379A (en) 1985-01-22 1986-04-22 Merrell Dow Pharmaceuticals Inc. Isoquinoline thromboxane synthetase inhibitors
US4822800A (en) 1986-06-09 1989-04-18 Ortho Pharmaceutical Corporation Isoquinolinol compounds having cardiotonic and phosphodiesterase fraction III inhibiting properties and/or renal vasodilating properties
US4882800A (en) * 1987-06-02 1989-11-28 Schueler Tyler E Flotation mattress
US4952588A (en) 1987-11-27 1990-08-28 Hoechst-Roussel Pharmaceuticals Inc. 1-aryl-3-quinoline-and 1-aryl-3-isoquinoline-carboxamides
US4966906A (en) 1987-11-27 1990-10-30 Hoechst-Roussel Pharmaceuticals Inc. 1-aryl-3-isoquinolinecarboxamides
BR9007558A (pt) * 1989-07-24 1992-06-23 A C I Int Ltd Material laminado aperfeicoado e processo para sua producao
ES2101420T3 (es) 1993-11-02 1997-07-01 Hoechst Ag Esteres-amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos.
EP0650961B1 (de) * 1993-11-02 1997-03-05 Hoechst Aktiengesellschaft Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
NZ270267A (en) 1993-12-30 1997-03-24 Hoechst Ag 3-hydroxypyridin-2yl (and -quinolin-2-yl) carboxamide derivatives and pharmaceutical compositions
JPH07226571A (ja) 1994-02-09 1995-08-22 Unitika Ltd プリント配線板用ガラス繊維織布及びその製造法
AU4515696A (en) 1994-12-12 1996-07-03 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
IL135495A (en) 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid
US6130231A (en) 1996-11-27 2000-10-10 Dupont Pharmaceuticals Integrin receptor antagonists
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
FR2779963A1 (fr) 1998-06-22 1999-12-24 Centre Nat Rech Scient Utilisation d'un compose possedant une affinite pour le recepteur mitochondrial des benzodiazepines en therapie du cancer
IT1302677B1 (it) 1998-10-15 2000-09-29 Zambon Spa Derivati benzazinici inibitori della fosfodiesterasi 4
WO2000064877A1 (en) 1999-04-26 2000-11-02 Neurogen Corporation 2-aminoquinolinecarboxamides: neurokinin receptor ligands
IT1320162B1 (it) 2000-02-09 2003-11-18 Rotta Research Lab Derivati della tirosina ad attivita' anti leucotrienica, procedimentoper la loro preparazione e loro uso farmaceutico.
FI20002044A0 (fi) 2000-09-15 2000-09-15 Orion Yhtymae Oyj Comt-entsyymiä estäviä naftaleenijohdannaisia
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
US6855510B2 (en) * 2001-03-20 2005-02-15 Dana Farber Cancer Institute, Inc. Pharmaceuticals and methods for treating hypoxia and screening methods therefor
WO2002074981A2 (en) * 2001-03-21 2002-09-26 Isis Innovation Ltd. Assays, methods and means relating to hypoxia inducible factor (hif) hydroxylase
GB0107901D0 (en) 2001-03-29 2001-05-23 Cyclacel Ltd Anti-cancer compounds
US6716866B2 (en) 2001-06-13 2004-04-06 Genesoft Pharmaceuticals, Inc. Aryl-benzimidazole compounds having antiinfective activity
US6777425B2 (en) 2001-06-13 2004-08-17 Genesoft Pharmaceuticals, Inc. Isoquinoline compounds having antiinfective activity
JP2003053997A (ja) 2001-08-22 2003-02-26 Canon Inc インクジェット記録装置、およびインクタンク
DE10154280A1 (de) * 2001-11-05 2003-05-15 Wilex Ag Antagonisten für alpha¶4¶-Integrine
US6762318B2 (en) 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
US20030176317A1 (en) * 2001-12-06 2003-09-18 Volkmar Guenzler-Pukall Stabilization of hypoxia inducible factor (HIF) alpha
US8318703B2 (en) 2001-12-06 2012-11-27 Fibrogen, Inc. Methods for improving kidney function
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
CN101518533A (zh) * 2002-12-06 2009-09-02 法布罗根股份有限公司 脂肪调节
GB0229581D0 (en) 2002-12-19 2003-01-22 Cyclacel Ltd Use
PL1644336T3 (pl) 2003-06-06 2011-07-29 Fibrogen Inc Związki heteroarylowe zawierające azot i ich zastosowanie w zwiększaniu poziomu endogennej erytropoetyny
US8614204B2 (en) * 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
US20060251638A1 (en) * 2003-06-06 2006-11-09 Volkmar Guenzler-Pukall Cytoprotection through the use of hif hydroxylase inhibitors
EP1646611A1 (en) 2003-07-15 2006-04-19 Merck & Co., Inc. Hydroxypyridine cgrp receptor antagonists
WO2005011696A1 (en) 2003-08-01 2005-02-10 Fibrogen, Inc. Inhibitors of 2-oxoglutarate dioxygenase as gamma globin inducers
JP2007501844A (ja) 2003-08-08 2007-02-01 トランス　テック　ファーマ，インコーポレイテッド アリール及びヘテロアリール化合物、組成物並びに使用方法
US7208601B2 (en) 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
KR101194123B1 (ko) 2004-03-16 2012-10-24 아사히 가세이 파마 가부시키가이샤 패수딜 함유 제제 및 그 안정성을 개선하는 방법
JP4792048B2 (ja) 2005-03-02 2011-10-12 ファイブロゲン インコーポレイティッド チエノピリジン化合物およびその使用方法
JP5390184B2 (ja) * 2005-06-06 2014-01-15 ファイブローゲン、インコーポレーテッド 貧血の改良された治療方法
CN101242817B (zh) 2005-06-15 2016-08-31 菲布罗根公司 HIF1α调节剂在治疗癌症中的用途
US7937393B2 (en) 2005-11-28 2011-05-03 Commvault Systems, Inc. Systems and methods for classifying and transferring information in a storage network
MX2008009581A (es) 2006-01-27 2009-01-07 Fibrogen Inc Compuestos de cianoisoquinolina que estabilizan el factor inducible hipoxia (fih).
CN101420980A (zh) 2006-02-16 2009-04-29 菲布罗根公司 治疗中风的化合物和方法
MX2008012734A (es) 2006-04-04 2009-01-29 Fibrogen Inc Compuestos pirrolo- y tiazolo-piridina como moduladores del factor inducible de hipoxia (hif).
US20100172984A1 (en) 2006-06-06 2010-07-08 Bijay Kumar Padhi tablet dosage form comprising cetirizine and pseudoephedrine
US7713986B2 (en) 2006-06-15 2010-05-11 Fibrogen, Inc. Compounds and methods for treatment of chemotherapy-induced anemia
US20070293575A1 (en) 2006-06-15 2007-12-20 Fibrogen, Inc. Compounds and methods for treatment of cancer-related anemia
TW200924768A (en) 2007-10-12 2009-06-16 Astrazeneca Ab Composition
EP2227475B1 (en) 2007-12-03 2014-02-19 Fibrogen, Inc. Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions
WO2009089547A1 (en) 2008-01-11 2009-07-16 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity
US8324405B2 (en) 2008-02-05 2012-12-04 Fibrogen, Inc. Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors
EP2334682B1 (en) 2008-08-20 2017-10-04 Fibrogen, Inc. Pyrrolo [ 1, 2 -b] pyridazine derivatives and their use as hif modulators
US8927591B2 (en) 2008-11-14 2015-01-06 Fibrogen, Inc. Thiochromene derivatives as HIF hydroxylase inhibitors
WO2012097331A1 (en) 2011-01-13 2012-07-19 Fibrogen, Inc. Methods for increasing reticulocyte hemoglobin content
US8921389B2 (en) 2011-02-02 2014-12-30 Fibrogen, Inc. Naphthyridine derivatives as inhibitors of hypoxia inducible factor (HIF) hydroxylase
JP6099644B2 (ja) 2011-07-22 2017-03-22 ベイジン ベータ ファーマシューティカルズ カンパニー， リミテッド プロリルヒドロキシラーゼ阻害剤としての化合物の多形体、およびその使用
US9409892B2 (en) 2012-03-09 2016-08-09 Fibrogen, Inc. 4-hydroxy-isoquinoline compounds as HIF hydroxylase inhibitors
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
SI3470397T1 (sl) 2012-07-16 2022-07-29 Fibrogen, Inc. Kristalinične oblike zaviralca prolil hidroksilaze
ES2631655T3 (es) 2012-07-16 2017-09-01 Fibrogen, Inc. Procedimiento para fabricar compuestos de isoquinolina
KR102233081B1 (ko) 2013-01-24 2021-03-29 피브로겐, 인크. 〔[1-시아노-5-(4-클로로페녹시)-4-하이드록시-아이소퀴놀린-3-카보닐]-아미노〕-아세트산의 결정 형태
DK3003284T3 (da) 2013-06-06 2020-03-30 Fibrogen Inc Farmaceutiske formuleringer af en hif-hydroxylase-inhibitor

Also Published As

Publication number Publication date
US7863292B2 (en) 2011-01-04
US9339527B2 (en) 2016-05-17
US8017625B2 (en) 2011-09-13
CA2528232C (en) 2010-05-25
PL1644336T3 (pl) 2011-07-29
CN102977015B (zh) 2015-05-06
AU2004245552A1 (en) 2004-12-16
KR100932169B1 (ko) 2009-12-16
JP2006527200A (ja) 2006-11-30
US8765956B2 (en) 2014-07-01
NO20060024L (no) 2006-01-30
PT1644336E (pt) 2011-04-21
US20070185159A1 (en) 2007-08-09
HRP20110272T1 (hr) 2011-06-30
JP2011148810A (ja) 2011-08-04
US20130178417A1 (en) 2013-07-11
WO2004108681A1 (en) 2004-12-16
US20130310565A1 (en) 2013-11-21
US8278325B2 (en) 2012-10-02
ES2362032T3 (es) 2011-06-27
CN103145616B (zh) 2015-09-30
BRPI0411055A (pt) 2006-07-25
US20170035747A1 (en) 2017-02-09
JP5684007B2 (ja) 2015-03-11
US20190240213A1 (en) 2019-08-08
CN103145616A (zh) 2013-06-12
DE602004031114D1 (de) 2011-03-03
CY1111616T1 (el) 2015-10-07
CN102977016A (zh) 2013-03-20
US20040254215A1 (en) 2004-12-16
US8916585B2 (en) 2014-12-23
SI1644336T1 (sl) 2011-06-30
US20070155784A1 (en) 2007-07-05
CN102977015A (zh) 2013-03-20
HK1090367A1 (en) 2006-12-22
US7629357B2 (en) 2009-12-08
US20080293763A1 (en) 2008-11-27
CN102718708A (zh) 2012-10-10
CN1816527A (zh) 2006-08-09
EP1644336B1 (en) 2011-01-19
AU2004245552B2 (en) 2010-01-21
CN102977016B (zh) 2015-01-14
ATE496033T1 (de) 2011-02-15
NO334949B1 (no) 2014-08-04
JP4776728B2 (ja) 2011-09-21
EP2357175A1 (en) 2011-08-17
US10646482B2 (en) 2020-05-12
US10092558B2 (en) 2018-10-09
IL171758A (en) 2013-02-28
EP1644336A1 (en) 2006-04-12
JP2010111697A (ja) 2010-05-20
CA2528232A1 (en) 2004-12-16
US20210060000A1 (en) 2021-03-04
US20140343094A1 (en) 2014-11-20
US7323475B2 (en) 2008-01-29
US20060217416A1 (en) 2006-09-28
KR20060025162A (ko) 2006-03-20
NZ543448A (en) 2009-02-28
BRPI0411055B1 (pt) 2018-08-21
US11229637B2 (en) 2022-01-25
US20120029011A1 (en) 2012-02-02

Similar Documents

Publication Publication Date Title
DK1644336T3 (da) Nitrogenholdige heteroarylforbindelser og deres anvendelse til forøgelse af endogent erythropoietin
CY1119624T1 (el) Κρυσταλλικες μορφες του 4-μεθυλο-ν-[3-(4-μεθυλ-ιμιδαζολ-1-υλ)-5-τριφθορομεθυλο-φαινυλο] -3 -(4-πυριδιν-3-υλ-πυριμιδιν-2-υλαμινο)-βενζαμιδιου
DK1776011T3 (da) Fungicid sammensætning, indeholdende et syreamidderivat
EA200701396A1 (ru) Триазолофталазины в качестве ингибиторов pde-2
DK1636593T3 (da) Modulering af vekselvirkningen mellem HGF-beta-kæde og c-met
ATE486597T1 (de) 3,4-substituierte pyrrolidin-derivate zur behandlung von hypertonie
DK1836169T3 (da) Sammensætninger og fremgangsmåder til behandling af celleproliferationslidelser
DK1765327T3 (da) Forbindelser, sammensætninger og fremgangsmåder
EA200801428A1 (ru) Производные пиридиазинона для лечения опухолей
DK1620437T3 (da) 5,7-diaminopyrazolo-4,3-d-pyrimidiner, der er anvendelige til behandling af hypertension
EA200800701A1 (ru) 4-замещенные пирролидин-2-оны и их применение
EA200801068A1 (ru) Производные четвертичного альфа-аминокарбоксамида в качестве модуляторов потенциалозависимых натриевых каналов
DK1833465T3 (da) Lyofilisering af virosomer
EA200801413A1 (ru) Гетероциклические сетр ингибиторы
ATE387452T1 (de) Spiroverbindungen mit npy antagonistischer wirkung
DK1709082T3 (da) Sammensætning til behandling af patologi knyttet til MSRV/HERV-W
DK1881830T3 (da) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinolin-derivater til behandling af infertilitet
ATE507222T1 (de) 1,1-dioxo-thiomorpholinyl-indolyl-methanon- derivate zur verwendung als h3-modulatoren
EA200901504A1 (ru) Производные пиразолона, как ингибиторы pde4
DK1620058T3 (da) Sammensætning til forbedring af kognition og hukommelse
DE602005014149D1 (de) Silanmerocyaninsulphonderivate, photoprotektive zusammensetzungen damit, verwendung davon als uv-filter
EA200901179A1 (ru) Замещённые тетрагидрохинолины
UA93886C2 (ru) Производные четвертичного альфа-аминокарбоксамида kak модуляторы потенциалозависимых натриевых каналов
BRPI0816810A2 (pt) utilização de pelo menos um composto, e, composto.
CR9529A (es) Anilidas de acido tiazolcarboxilico